7stories.uk
MHRA's New Strategy: Innovation and Global Collaboration Post-Brexit
NewJuly 22, 202503:31

MHRA's New Strategy: Innovation and Global Collaboration Post-Brexit

How is the MHRA rebranding itself as a fast, innovative regulatory body in the life sciences sector? Learn about their 10-year NHS revitalization plan and global partnerships.

0:003:31
Speed:

In this episode of the UK Business Morning, Alice and Lewis discuss the MHRA's new post-Brexit strategy, focusing on innovation in AI and gene therapies while outsourcing routine drug approvals to overseas regulators. We explore the challenges the agency faced after Brexit, including resource cuts and missed targets, and how the MHRA is now working to regain its competitiveness. With the introduction of the international recognition procedure and a 10-year NHS revitalization plan, the MHRA aims to cut clinical trial approval times and position the UK as a global leader in healthcare regulation. Tune in to learn more about the MHRA's efforts to attract pharmaceutical companies and ensure the UK remains a top destination for clinical trials.